drugset / Trial / NCT07594509
Perioperative Vericiguat in Patients Undergoing Cardiovascular Surgery
Not yet recruiting
600 enrolled
Nanjing Medical University
Beijing Anzhen Hospital · collabChangzhou First People's Hospital · collabShanghai East Hospital, China · collabThe Affiliated Hospital of Qingdao University · collabThe First Affiliated Hospital of Bengbu Medical University · collabThe First Affiliated Hospital of Guangzhou Medical University · collabWest China Hospital · collab
RandomizedParallel-groupSingle-blindPrevention
Summary
The purpose of this study is to evaluate the efficacy and safety of perioperative vericiguat in patients undergoing cardiovascular surgery. Patients at high risk of heart failure or with confirmed cardiac dysfunction will be randomly assigned to receive either vericiguat plus standard of care or standard of care alone. The primary objective is to determine whether perioperative administration of vericiguat can reduce (I) the Incidence of Early Postoperative Hemodynamic Deterioration or Clinically Significant Myocardial Injury; (II) Incidence of Major Sterile Inflammation-Related Organ Injuries (MSIRI), and the incidence of Major Adverse Cardiovascular Events (MACE) within 12 months after surgery.
Timeline
- Start
- 2026-05-31
- Primary completion
- 2028-12-31
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vericiguat | Other / unclassified | 10 mg | Oral |